<?xml version='1.0' encoding='UTF-8'?>
<rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0">
  <channel>
    <title>Best Of Week - Head &amp; Neck Cancer</title>
    <link>https://pubmed.ncbi.nlm.nih.gov</link>
    <description>Top 10 most impactful head and neck cancer papers this week, selected by AI</description>
    <lastBuildDate>Tue, 23 Dec 2025 07:02:47 +0000</lastBuildDate>
    <item>
      <title>#1 [85/100] INDUCE-3: A randomized Phase II/III study of first-line feladilimab plus pembrolizumab in patients with recurrent/metastatic head and neck squamous cell carcinoma.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41427951/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41427951/</guid>
      <dc:creator>Rischin D, Hansen AR, Cohen EEW, Tahara M, Harrington KJ, Haddad RI, Licitra L, Mehanna H, Ferris RL, Koralewski P, et al.</dc:creator>
      <pubDate>Mon, 22 Dec 2025 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;‚≠ê HIGH IMPACT - Score: 85/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This is a randomized Phase II/III study evaluating a novel combination therapy in a relevant patient population, with potential implications for treatment guidelines and overall survival outcomes.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Rischin D, Hansen AR, Cohen EEW, Tahara M, Harrington KJ, Haddad RI, Licitra L, Mehanna H, Ferris RL, Koralewski P, et al.&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Clinical cancer research : an official journal of the American Association for Cancer Research | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1158/1078-0432.CCR-25-1197'&gt;10.1158/1078-0432.CCR-25-1197&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2025-Dec-22&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41427951/'&gt;41427951&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;PURPOSE: Feladilimab, an inducible T-cell co‚Äëstimulatory receptor agonist, demonstrated clinical activity in combination with pembrolizumab in a Phase I head and neck squamous cell carcinoma (HNSCC) expansion cohort, prompting further evaluation in patients in this setting. PATIENTS AND METHODS: INDUCE-3 (NCT04128696) was a randomized, double-blind, Phase II/III study in first-line programmed death-ligand 1-positive recurrent and/or metastatic HNSCC patients. A 2-in-1 adaptive design was implemented, with an option to expand the Phase II study into a Phase III confirmatory study. Patients were randomized 1:1 to receive feladilimab plus pembrolizumab or placebo plus pembrolizumab; up to 35 cycles of treatment for approximately 2 years. Primary endpoints were overall survival (OS) and investigator-assessed progression-free survival (PFS). RESULTS: The study enrolled 315 patients. Following review of unblinded interim data in 140 patients, an Independent Data Monitoring Committee recommended stopping patient accrual based on prespecified criteria. Existing patients discontinued feladilimab or placebo. Pembrolizumab treatment continued until prespecified stopping criteria were met. This study demonstrated no evidence of an effect in favor of feladilimab plus pembrolizumab, with an adjusted HR of 1.51 for OS and 1.40 for PFS (median OS: 44.1 weeks [95% confidence interval (CI): 35.9-NA]; median PFS: 10.1 weeks [95% CI: 9.1-15.0]) versus placebo plus pembrolizumab (median OS: not reached; median PFS: 16.0 weeks [95% CI: 14.3-26.1]). The incidence of treatment-related adverse events was higher in the placebo group. CONCLUSIONS: This analysis does not support the combination of feladilimab plus pembrolizumab due to lack of superiority over placebo plus pembrolizumab.</description>
    </item>
    <item>
      <title>#2 [75/100] Effects of exercise on head and neck cancer surgery: a systematic review of randomized controlled trials.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41430445/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41430445/</guid>
      <dc:creator>Ekici E, Y√ºzba≈üƒ±oƒülu √ú, √ñzkeskin M, √ñzden F</dc:creator>
      <pubDate>Mon, 22 Dec 2025 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;‚ú® NOTABLE - Score: 75/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This systematic review of randomized controlled trials addresses an important clinical question regarding postoperative care in head and neck cancer patients, with potential implications for improving quality of life, although it does not present new primary data or practice-changing findings.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Ekici E, Y√ºzba≈üƒ±oƒülu √ú, √ñzkeskin M, √ñzden F&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1007/s00405-025-09905-9'&gt;10.1007/s00405-025-09905-9&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2025-Dec-22&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41430445/'&gt;41430445&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;PURPOSE: Understanding and optimizing exercise programs for individuals undergoing head and neck cancer (HNC) surgery is essential for improving postoperative quality of life. This review aims to examine the effects of exercise and physiotherapy interventions on various outcomes in individuals who have undergone HNC surgery. METHODS: PubMed, Web of Science, and Scopus were systematically searched for randomized controlled trials published within the past decade, yielding 14 studies that met the inclusion criteria. Methodological quality and risk of bias were assessed using the Physiotherapy Evidence Database (PEDro) scale. RESULTS: Except for one preoperative instruction session, all interventions were implemented postoperatively. The most frequently evaluated outcomes included shoulder, jaw, and swallowing function, as well as postoperative symptoms. Across studies, exercise programs with varying content consistently improved shoulder mobility, swallowing function, and symptom burden. CONCLUSION: Evidence from current studies demonstrates that exercise interventions contribute to improved functional outcomes and reduced symptom burden, supporting their inclusion as a core component of standard care in patients who have undergone head and neck cancer surgery.</description>
    </item>
    <item>
      <title>#3 [75/100] Efficacy and safety of Mepitel film for radiodermatitis: a systematic review and meta-analysis.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41420160/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41420160/</guid>
      <dc:creator>Ren X, Wang H, Liu J, Yuan Y, Wu T, Zhang H, Yang D, Yan Y, Xu Y, Wei F</dc:creator>
      <pubDate>Fri, 19 Dec 2025 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;‚ú® NOTABLE - Score: 75/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This systematic review and meta-analysis includes a substantial number of studies (27) and over 2,300 patients, providing important insights into the efficacy of Mepitel film for radiodermatitis, which could influence clinical practice in managing treatment-related skin toxicity.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Ren X, Wang H, Liu J, Yuan Y, Wu T, Zhang H, Yang D, Yan Y, Xu Y, Wei F&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; BMC cancer | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1186/s12885-025-15465-2'&gt;10.1186/s12885-025-15465-2&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2025-Dec-19&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41420160/'&gt;41420160&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;OBJECTIVE: To evaluate the effects of Mepitel film on the prevention and treatment of radiodermatitis. METHODS: We conducted a systematic search across multiple databases, including PubMed, Cochrane Library, Embase, China National Knowledge Infrastructure (CNKI), Wanfang Database, and SinoMed Database, from their inception until August 6, 2024. We identified randomized controlled trials (RCTs) or controlled clinical trials that assessed the effects of Mepitel film on radiodermatitis. The risk of bias was evaluated using the Revised Cochrane Risk-of-Bias tool for randomized trials (RoB2). Traditional meta-analysis was performed using RevMan 5.3 and Stata 14.0 software. RESULTS: A total of 27 studies involving 2,313 cancer patients were included. The pooled analysis indicated that Mepitel significantly reduced the incidence of radiation dermatitis (OR‚Äâ=‚Äâ0.28, 95%CI 0.16 to 0.50, I2‚Äâ=‚Äâ67%, P‚Äâ&lt;‚Äâ0.0001) compared to the control groups. In the subgroup analysis by cancer type, Mepitel reduced the incidence of radiation dermatitis in nasopharyngeal carcinoma (OR‚Äâ=‚Äâ0.25, 95%CI 0.13 to 0.46, I2‚Äâ=‚Äâ0%, P‚Äâ&lt;‚Äâ0.0001), breast cancer (OR‚Äâ=‚Äâ0.42, 95%CI 0.26 to 0.68, I2‚Äâ=‚Äâ24%, P‚Äâ=‚Äâ0.0004), and various malignancies (OR‚Äâ=‚Äâ0.10, 95%CI 0.06 to 0.16, I2‚Äâ=‚Äâ0%, P‚Äâ&lt;‚Äâ0.00001). Mepitel use was also associated with a lower incidence of moderate and severe skin injury in radiotherapy patients (RTOG grade II OR‚Äâ=‚Äâ0.26, 95%CI 0.16 to 0.42, P‚Äâ&lt;‚Äâ0.00001; RTOG grade III OR‚Äâ=‚Äâ0.19, 95%CI 0.12 to 0.30, P‚Äâ&lt;‚Äâ0.00001; RTOG grade IV OR‚Äâ=‚Äâ0.10, 95%CI 0.03 to 0.36, P‚Äâ=‚Äâ0.0005), as well as a reduction in the severity of radiation-induced skin damage (combined RISRAS score, MD= -0.74 95% CI -1.02 to -0.46, I2‚Äâ=‚Äâ95%, P‚Äâ&lt;‚Äâ0.00001; researcher RISRAS score MD= -0.47 95% CI -0.67 to -0.27, I2‚Äâ=‚Äâ90%, P‚Äâ&lt;‚Äâ0.00001; and patient RISRAS score MD= -1.19 95% CI -1.33 to -1.05, I2‚Äâ=‚Äâ39%, P‚Äâ&lt;‚Äâ0.00001). Additionally, patients treated with Mepitel experienced fewer cases of moist desquamation (OR‚Äâ=‚Äâ0.46, 95%CI 0.25 to 0.83, I2‚Äâ=‚Äâ58%, P‚Äâ=‚Äâ0.010), and shorter healing times (MD= -4.73, 95%CI -7.16 to -2.30, I2‚Äâ=‚Äâ98%, P‚Äâ=‚Äâ0.0001). CONCLUSION: Mepitel interventions significantly reduced RTOG grades and RISRAS scores, decreased the risk of moist desquamation, and shortened healing times for radiation-induced dermatitis in cancer patients. Further clinical studies are needed to better understand the relationship between Mepitel and radiation dermatitis in this patient population.</description>
    </item>
    <item>
      <title>#4 [75/100] Pathologic Response and Survival After Neoadjuvant Immunotherapy for Resectable Mucosal HNSCC: A Systematic Review and Meta-Analysis.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41410931/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41410931/</guid>
      <dc:creator>Mastrolonardo EV, De Ravin E, Kaki PC, Estephan LE, Nunes K, Kenny H, Bridgham K, Tasoulas J, Koeneman SH, Goldman RA, et al.</dc:creator>
      <pubDate>Thu, 18 Dec 2025 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;‚ú® NOTABLE - Score: 75/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This systematic review and meta-analysis addresses an important clinical question regarding the association between pathologic treatment response and survival in neoadjuvant immunotherapy for HNSCC, providing valuable insights that could influence future treatment strategies.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Mastrolonardo EV, De Ravin E, Kaki PC, Estephan LE, Nunes K, Kenny H, Bridgham K, Tasoulas J, Koeneman SH, Goldman RA, et al.&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; JAMA otolaryngology-- head &amp; neck surgery | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1001/jamaoto.2025.4573'&gt;10.1001/jamaoto.2025.4573&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2025-Dec-18&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41410931/'&gt;41410931&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;IMPORTANCE: Numerous phase 2 trials have evaluated the efficacy of neoadjuvant immune checkpoint inhibition (ICI) for mucosal head and neck squamous cell carcinoma (HNSCC), using some degree of pathologic treatment response as a primary or secondary end point. However, whether pathologic treatment response is a meaningful surrogate end point for survival has yet to be determined. OBJECTIVE: To systematically assess the association between pathologic treatment response and overall survival (OS) and disease-free survival (DFS) after neoadjuvant ICI. DATA SOURCES: A systematic search of the PubMed, OVID Medline, Embase, CINAHL, and Cochrane databases was performed from January 1, 2000, through May 31, 2025. STUDY SELECTION: Peer-reviewed studies investigating neoadjuvant ICI for the treatment of mucosal HNSCC in patients 18 years and older were identified. Full-length English-language articles that presented pathologic treatment response and survival data (OS and/or DFS) and any association between the 2 were included. DATA EXTRACTION AND SYNTHESIS: Three blinded reviewers independently extracted study characteristics, pathologic treatment response data, and survival data, including hazard ratios (HRs) and CIs when available, according to PRISMA guideline. Data were compiled for statistical analysis to calculate DFS, OS, and HRs using a random-effects model. The I2 index was used to report data heterogeneity. MAIN OUTCOMES AND MEASURES: HRs for the association of pathologic treatment response with DFS and OS. RESULTS: Eleven trials involving 451 patients met inclusion criteria, with 368 patients included in this meta-analysis. Nine nonrandomized and 2 randomized studies were included, including 7 cohort studies, 2 randomized clinical trials, and 2 retrospective cohort studies, each with a different neoadjuvant ICI regimen. Pooled analysis demonstrated that overall (primary tumor‚Äâplus‚Äâlymph node) partial pathologic response (PPR; ‚â§50% residual viable tumor; HR, 0.53; 95% CI, 0.28-0.97; I2‚Äâ=‚Äâ2.1%) and major pathologic response (MPR; ‚â§10% residual viable tumor; HR, 0.34; 95% CI, 0.12-0.93; I2‚Äâ=‚Äâ0.0%) were both associated with improved DFS up to 2 years. PPR and MPR were not associated with improved OS. Nine of 11 studies were at low risk of bias. CONCLUSIONS AND RELEVANCE: Study findings suggest that overall PPR and MPR are associated with improved DFS. These data provide additional support for the potential use of pathologic treatment response as a surrogate for DFS after neoadjuvant ICI in resectable mucosal HNSCC.</description>
    </item>
    <item>
      <title>#5 [70/100] NPC-SurvAI: A fully automated deep learning framework for prognostic prediction and risk stratification in patients with nasopharyngeal carcinoma.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41429722/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41429722/</guid>
      <dc:creator>You J, Ou H, Zhang Y, Wu X, Zhang L, Jin Z, Chen Q, Shen H, Liu X, Sun J, et al.</dc:creator>
      <pubDate>Thu, 01 Jan 2026 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;‚ú® NOTABLE - Score: 70/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This study presents a large retrospective analysis with over 2000 patients, utilizing a novel deep learning framework for prognostic prediction in nasopharyngeal carcinoma, which could have significant clinical implications, although it is not a randomized controlled trial.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; You J, Ou H, Zhang Y, Wu X, Zhang L, Jin Z, Chen Q, Shen H, Liu X, Sun J, et al.&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1016/j.radonc.2025.111223'&gt;10.1016/j.radonc.2025.111223&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2026-Jan-01&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41429722/'&gt;41429722&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;BACKGROUND AND PURPOSE: Deep learning can non-invasively depict the radiological phenotype of tumor. We aimed to propose an end-to-end deep learning framework called NPC-SurvAI to perform prognosis assessment using MRI in nasopharyngeal carcinoma (NPC). METHODS: This retrospective study included 2180 NPC patients who underwent baseline MRI. The NPC-SurvAI comprised an AttVNet for image segmentation and a DenseNet-ICAM for prognosis evaluation, including progression-free survival (PFS) and overall survival (OS). The clinical model was built with age, T-stage, N-stage, and EBV DNA. The image and combined models were developed by the NPC-SurvAI framework. The integrated area under the curve (iAUC) and thetime-dependent AUC (tAUC) were leveraged to measure the predictive accuracy. K-means clustering and Kaplan-Meier survival analysis were utilized to stratify patients into subtypes and compare their prognoses. RESULTS: In the validation cohorts, the AttVNet achieved average Dice similarity coefficients of 0.726-0.764 tumor segmentation. The dynamic change curves of the AUCs over time suggested that the combined model outperformed both the clinical and image models in predicting PFS (iAUC: 0.838-0.884 vs 0.788-0.844 vs 0.738-0.798) and OS (iAUC: 0.842-0.894 vs 0.793-0.853 vs 0.754-0.807) at any time point from 1 to 8‚ÄØyears. Specially, the combined model achieved time-AUCs of 0.844-0.930 for 3-year PFS and 0.827-0.896 for 5-year PFS; 0.838-0.978 for 3-year OS and 0.788-0.871 for 5-year OS. Additionally, patients could be stratified into two subtypes with different survivals (all P‚ÄØ&lt;‚ÄØ0.05). CONCLUSIONS: NPC-SurvAI has the potential to automatically stratify patients with diverse prognoses, which helps clinicians in optimizing treatment decisions and surveillance.</description>
    </item>
    <item>
      <title>#6 [70/100] The actual performance of ML/AI models in predicting radiation-induced toxicity in head and neck cancer: a systematic review and meta-analysis.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41421773/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41421773/</guid>
      <dc:creator>Ugwu GC, Jalali F, Liu G, Li G, Langendijk JA, Alizadeh BZ</dc:creator>
      <pubDate>Thu, 18 Dec 2025 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;‚ú® NOTABLE - Score: 70/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This systematic review and meta-analysis evaluates the performance of AI/ML models in predicting radiation-induced toxicity in head and neck cancer, providing important insights into their reliability and clinical applicability, though it does not present primary data or novel therapeutic findings.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Ugwu GC, Jalali F, Liu G, Li G, Langendijk JA, Alizadeh BZ&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1016/j.radonc.2025.111350'&gt;10.1016/j.radonc.2025.111350&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2025-Dec-18&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41421773/'&gt;41421773&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;An increasing number of Artificial intelligence (AI) and machine learning (ML) models are being developed to predict radiation-induced toxicities (RITs) in patients with head and neck cancer (HNC). But their performance and reliability remain uncertain. This systematic review and meta-analysis evaluated the predictive accuracy and methodological quality of these models. We comprehensively searched PubMed, EMBASE, Web of Science, and the Cochrane Library to identify studies reporting on ML/AI models for predicting RITs in HNC patients. Eligible studies were assessed for bias risk using the PROBAST tool, and key performance metrics, including the area under the receiver operating curve (AUROC), were extracted. A hierarchical multilevel meta-analysis was performed to estimate pooled AUC values, and subgroup analyses explored the influence of study characteristics on model performance. A total of 67 studies with a total of 568 models were included, showing moderate discriminatory power of ML/AI models, with a pooled AUC = 0.76; 95‚ÄØ% CI: 0.73-0.78. Nonetheless, substantial heterogeneity was observed across studies. Incorporating imaging biomarkers significantly improved model performance. Prospective and internal validation showed comparable performance; external validation shows true generalizability. The predominance of retrospective designs and variability in predictor selection may have introduced bias, affecting model reliability and generalisability. ML/AI models hold promise for predicting RITs in HNC patients, but methodological constraints limit their applicability. Standardised and transparent reporting of model development and validation processes is vital for improving comparability among studies. Future research should explore hybrid modelling methods and the integration of clinical, dosimetric, radiomic, and genomic data to boost predictive accuracy.</description>
    </item>
    <item>
      <title>#7 [70/100] Pembrolizumab in Head and Neck Cancer-Promise and Price.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41410927/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41410927/</guid>
      <dc:creator>Miller LE, Rocco JW, Rathi VK</dc:creator>
      <pubDate>Thu, 18 Dec 2025 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;‚ú® NOTABLE - Score: 70/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; The paper discusses pembrolizumab in head and neck cancer, which is a relevant and important topic, likely providing insights into its clinical application, but without details on study design or outcomes, it does not meet the criteria for high impact.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Miller LE, Rocco JW, Rathi VK&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; JAMA otolaryngology-- head &amp; neck surgery | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1001/jamaoto.2025.4624'&gt;10.1001/jamaoto.2025.4624&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2025-Dec-18&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41410927/'&gt;41410927&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;i&gt;No abstract available&lt;/i&gt;</description>
    </item>
    <item>
      <title>#8 [70/100] Differences in Survival Following Surgery Versus Chemoradiotherapy for Clinical Stage T4a Laryngeal Squamous Cell Carcinoma: A Propensity Score-Matched Analysis.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41403196/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41403196/</guid>
      <dc:creator>Fu BJ, Potter AL, Pipkorn P, Kraimer KL, Chen MM, Rajasekaran K, Yang CJ, Lee JJ</dc:creator>
      <pubDate>Tue, 16 Dec 2025 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;‚ú® NOTABLE - Score: 70/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This study utilizes a large retrospective cohort analysis with a significant sample size (n=3569), providing important insights into survival outcomes for cT4a laryngeal squamous cell carcinoma. While it may not be a randomized controlled trial, the findings could influence treatment decisions and understanding of therapeutic options.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Fu BJ, Potter AL, Pipkorn P, Kraimer KL, Chen MM, Rajasekaran K, Yang CJ, Lee JJ&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Head &amp; neck | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1002/hed.70114'&gt;10.1002/hed.70114&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2025-Dec-16&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41403196/'&gt;41403196&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;BACKGROUND: Although laryngeal cancer incidence has declined in the United States, case fatality has risen. The survival equivalence of surgery versus chemoradiotherapy (CRT) for cT4a laryngeal squamous cell carcinoma (LSCC) remains uncertain. METHODS: We conducted a retrospective cohort study of cT4a LSCC patients treated with curative-intent surgery or CRT using the National Cancer Database (2010-2021). Those receiving neoadjuvant or palliative therapy, or with distant metastases were excluded. Survival was assessed using Kaplan-Meier and Cox models after 1:1 propensity score matching. RESULTS: Among 3569 patients (mean age 61.0, 708 female), 2437 (68.3%) underwent surgery while 1132 (31.7%) received CRT. In the matched cohort (n‚Äâ=‚Äâ452 per arm), median survival was 52.8 (95% CI: 45.6-62.4) versus 37.6 (95% CI: 29.2-45.4) months for surgery versus CRT. Adjusted HR for CRT relative to surgery was 1.26 (95% CI: 1.02-1.57). CONCLUSIONS: Surgery was associated with improved overall survival compared with definitive CRT in patients with T4a LSCC.</description>
    </item>
    <item>
      <title>#9 [65/100] Greater Attention to Gingival Cancer and Floor of Mouth Cancer: Based on a Retrospective Analysis of Oral Cancer Across Different Subsites.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41424359/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41424359/</guid>
      <dc:creator>Li H, Ding Y, Wu Y, Fang Y, Li X, Shi W, Chen S, Yang A, Zhang J, Shi R, et al.</dc:creator>
      <pubDate>Mon, 22 Dec 2025 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;üìå SELECTED - Score: 65/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This study is a large retrospective analysis with 885 patients, providing important insights into the clinicopathological characteristics and survival outcomes of gingival and floor of mouth cancers, which may influence future clinical considerations.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Li H, Ding Y, Wu Y, Fang Y, Li X, Shi W, Chen S, Yang A, Zhang J, Shi R, et al.&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Head &amp; neck | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1002/hed.70145'&gt;10.1002/hed.70145&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2025-Dec-22&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41424359/'&gt;41424359&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;BACKGROUND: The gingiva and floor of the mouth are distinct subsites, and oral squamous cell carcinoma (OSCC) originating in these locations warrants further indepth understanding. METHODS: This study enrolled patients with OSCC from 2000 to 2020, and analyzed the clinicopathological characteristics. Kaplan-Meier analysis compared overall survival (OS) and recurrence-free survival (RFS). Univariate analysis and multivariate Cox proportional hazards model examined the risk factors on survival outcomes. RESULTS: A total of 885 OSCC patients were included, with the most common tumor subsites: oral tongue (41.9%), gingiva (31.8%), and floor of mouth (16.0%). Gingival and floor of mouth showed a higher proportion of advanced stage (65.8%, 66.9%) and significantly poorer OS (3-year: 63.0%, 57.0%; 5-year: 49.8%, 37.3%) and RFS (3-year: 59.1%, 61.3%; 5-year: 55.5%, 57.0%). Neoadjuvant chemotherapy was associated with significantly reduced mortality in gingival cancer (HR‚Äâ=‚Äâ0.598), while tobacco exposure (HR‚Äâ=‚Äâ1.952) was associated with a significant increase in mortality in floor of mouth cancer. CONCLUSION: Gingival cancer and floor of mouth cancer have a worse prognosis, and thus require greater attention throughout the entire management process.</description>
    </item>
    <item>
      <title>#10 [65/100] Feasibility and Adherence to Home-Based Intensive Treatment Programs for Chronic Radiation-Associated Dysphagia in Head and Neck Cancer Survivors-The HIT-CRAD Trial.</title>
      <link>https://pubmed.ncbi.nlm.nih.gov/41420436/</link>
      <guid>https://pubmed.ncbi.nlm.nih.gov/41420436/</guid>
      <dc:creator>Massonet H, Goeleven A, Nuyts S, Vergauwen A, Baudelet M, Duprez F, Tomassen P, Van den Steen L, Van Nuffelen G</dc:creator>
      <pubDate>Sat, 20 Dec 2025 12:00:00 +0000</pubDate>
      <description>&lt;h3&gt;üìå SELECTED - Score: 65/100&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Why this matters:&lt;/b&gt; This study presents a randomized trial with a focus on a novel home-based treatment for chronic radiation-associated dysphagia in head and neck cancer survivors, demonstrating feasibility and adherence, but lacks large sample size and significant clinical outcomes that would indicate a higher impact.&lt;/p&gt;&lt;hr/&gt;&lt;b&gt;Authors:&lt;/b&gt; Massonet H, Goeleven A, Nuyts S, Vergauwen A, Baudelet M, Duprez F, Tomassen P, Van den Steen L, Van Nuffelen G&lt;br/&gt;&lt;b&gt;Journal:&lt;/b&gt; Head &amp; neck | &lt;b&gt;DOI:&lt;/b&gt; &lt;a href='https://doi.org/10.1002/hed.70136'&gt;10.1002/hed.70136&lt;/a&gt;&lt;br/&gt;&lt;b&gt;Published:&lt;/b&gt; 2025-Dec-20&lt;br/&gt;&lt;b&gt;PMID:&lt;/b&gt; &lt;a href='https://pubmed.ncbi.nlm.nih.gov/41420436/'&gt;41420436&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;b&gt;Abstract:&lt;/b&gt;&lt;br/&gt;BACKGROUND: The HIT-CRAD trial (ISRCTN57028065) is the first to combine home-based non-invasive brain stimulation with high-volume strength and skill training over 8‚Äâweeks in patients with chronic radiation-associated dysphagia (CRAD) following primary (chemo)radiotherapy for head and neck cancer. METHODS: Fifty-four patients were randomized into three groups. Group 1 performed 8‚Äâweeks of strength training. Groups 2 and 3 combined 4‚Äâweeks of strength training with 4‚Äâweeks of skill training. Group 3 received high-definition transcranial direct current stimulation (HD-tDCS) during training. Group 2 received sham HD-tDCS. RESULTS: Overall adherence and exercise adherence remained above 75% across all groups. Home-based HD-tDCS proved safe and feasible, with mild to moderate side effects (tingling, itching, or burning). Median exercise performance levels for strength training exercises ranged from 94% to 100%. CONCLUSIONS: This study confirms the feasibility of high-volume strength and skill training with HD-tDCS in patients with C-RAD. Proactive adherence-supporting factors facilitate high adherence in this population. Both real and sham HD-tDCS proved safe, feasible, and well tolerated. TRIAL REGISTRATION: International Standard Randomized Controlled Trials Number (ISRCTN) registry ID ISRCTN57028065.</description>
    </item>
  </channel>
</rss>
